{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T12:26:45Z","timestamp":1775910405529,"version":"3.50.1"},"reference-count":58,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,18]],"date-time":"2023-01-18T00:00:00Z","timestamp":1674000000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R01AI166682-01"],"award-info":[{"award-number":["R01AI166682-01"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R56AI143937-01A1"],"award-info":[{"award-number":["R56AI143937-01A1"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R56AI153600-01A1"],"award-info":[{"award-number":["R56AI153600-01A1"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["OPP1109889"],"award-info":[{"award-number":["OPP1109889"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005624","name":"PATH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005624","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.vaccine.2023.01.033","type":"journal-article","created":{"date-parts":[[2023,1,31]],"date-time":"2023-01-31T19:13:03Z","timestamp":1675192383000},"page":"1589-1601","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Route and antigen shape immunity to dmLT-adjuvanted vaccines to a greater extent than biochemical stress or formulation excipients"],"prefix":"10.1016","volume":"41","author":[{"given":"Addison E.","family":"Stone","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saraswatie","family":"Rambaran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7459-5017","authenticated-orcid":false,"given":"Ivy V.","family":"Trinh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcus","family":"Estrada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Curtis W.","family":"Jarand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Blake S.","family":"Williams","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6530-1718","authenticated-orcid":false,"given":"Amelie E.","family":"Murrell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chelsea M.","family":"Huerter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William","family":"Bai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Surya","family":"Palani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukihiro","family":"Nakanishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0559-4114","authenticated-orcid":false,"given":"Renee M.","family":"Laird","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frederic M.","family":"Poly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wayne F.","family":"Reed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1932-6345","authenticated-orcid":false,"given":"Jessica A.","family":"White","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth B.","family":"Norton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2023.01.033_b0005","doi-asserted-by":"crossref","DOI":"10.1128\/CMR.00084-18","article-title":"Factors That Influence the Immune Response to Vaccination","volume":"32","author":"Zimmermann","year":"2019","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.vaccine.2023.01.033_b0010","article-title":"Optimizing the utilization of aluminum adjuvants in vaccines: you might just get what you want","volume":"3","author":"Harm HogenEsch","year":"2018","journal-title":"npj Vaccines"},{"key":"10.1016\/j.vaccine.2023.01.033_b0015","doi-asserted-by":"crossref","unstructured":"Clements JD, Norton EB. The Mucosal Vaccine Adjuvant LT(R192G\/L211A) or dmLT. mSphere. 2018;3.","DOI":"10.1128\/mSphere.00215-18"},{"key":"10.1016\/j.vaccine.2023.01.033_b0020","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1128\/CVI.00538-10","article-title":"Characterization of a mutant Escherichia coli heat-labile toxin, LT(R192G\/L211A), as a safe and effective oral adjuvant","volume":"18","author":"Norton","year":"2011","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2023.01.033_b0025","doi-asserted-by":"crossref","unstructured":"Clements JD, Norton EB. Minireview: The Mucosal Vaccine Adjuvant LT(R192G\/L211A) or dmLT. mSphere. 2018.","DOI":"10.1128\/mSphere.00215-18"},{"key":"10.1016\/j.vaccine.2023.01.033_b0030","doi-asserted-by":"crossref","unstructured":"Norton EB, Lawson LB, Mahdi Z, Freytag LC, Clements JD. The A subunit of Escherichia coli heat-labile enterotoxin functions as a mucosal adjuvant and promotes IgG2a, IgA, and Th17 responses to vaccine antigens. Infect Immun. 2012;80:2426-35.","DOI":"10.1128\/IAI.00181-12"},{"key":"10.1016\/j.vaccine.2023.01.033_b0035","doi-asserted-by":"crossref","first-page":"e0227047","DOI":"10.1371\/journal.pone.0227047","article-title":"LTA1 and dmLT enterotoxin-based proteins activate antigen-presenting cells independent of PKA and despite distinct cell entry mechanisms","volume":"15","author":"Valli","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2023.01.033_b0040","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1128\/IAI.01559-08","article-title":"Cholera toxin and Escherichia coli heat-labile enterotoxin, but not their nontoxic counterparts, improve the antigen-presenting cell function of human B lymphocytes","volume":"77","author":"Negri","year":"2009","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2023.01.033_b0045","doi-asserted-by":"crossref","first-page":"2870","DOI":"10.1128\/iai.59.9.2870-2879.1991","article-title":"Effect of site-directed mutagenic alterations on ADP-ribosyltransferase activity of the A subunit of Escherichia coli heat-labile enterotoxin","volume":"59","author":"Lobet","year":"1991","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2023.01.033_b0050","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S0264-410X(99)00168-1","article-title":"The role of cAMP in mucosal adjuvanticity of Escherichia coli heat-labile enterotoxin (LT)","volume":"18","author":"Cheng","year":"1999","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.01.033_b0055","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1002\/eji.1830220915","article-title":"The adjuvant effect of Vibrio cholerae and Escherichia coli heat-labile enterotoxins is linked to their ADP-ribosyltransferase activity","volume":"22","author":"Lycke","year":"1992","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.vaccine.2023.01.033_b0060","doi-asserted-by":"crossref","unstructured":"Norton EB, Branco LM, Clements JD. Evaluating the A-Subunit of the Heat-Labile Toxin (LT) As an Immunogen and a Protective Antigen Against Enterotoxigenic Escherichia coli (ETEC). PloS one. 2015;10:e0136302.","DOI":"10.1371\/journal.pone.0136302"},{"key":"10.1016\/j.vaccine.2023.01.033_b0065","doi-asserted-by":"crossref","first-page":"15128","DOI":"10.1038\/s41598-019-51356-w","article-title":"LTA1 is a safe, intranasal enterotoxin-based adjuvant that improves vaccine protection against influenza in young, old and B-cell-depleted (muMT) mice","volume":"9","author":"Valli","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.vaccine.2023.01.033_b0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2019.02.025","article-title":"Live attenuated enterotoxigenic Escherichia coli (ETEC) vaccine with dmLT adjuvant protects human volunteers against virulent experimental ETEC challenge","author":"Harro","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.01.033_b0075","doi-asserted-by":"crossref","first-page":"e51718","DOI":"10.1371\/journal.pone.0051718","article-title":"The adjuvant double mutant Escherichia coli heat labile toxin enhances IL-17A production in human T cells specific for bacterial vaccine antigens","volume":"7","author":"Leach","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2023.01.033_b0080","doi-asserted-by":"crossref","first-page":"7077","DOI":"10.1016\/j.vaccine.2014.10.069","article-title":"Safety and immunogenicity of an improved oral inactivated multivalent enterotoxigenic Escherichia coli (ETEC) vaccine administered alone and together with dmLT adjuvant in a double-blind, randomized, placebo-controlled Phase I study","volume":"32","author":"Lundgren","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.01.033_b0085","doi-asserted-by":"crossref","first-page":"3132","DOI":"10.1016\/j.vaccine.2016.04.055","article-title":"Induction of long term mucosal immunological memory in humans by an oral inactivated multivalent enterotoxigenic Escherichia coli vaccine","volume":"34","author":"Lundgren","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.01.033_b0090","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1111\/j.1651-2227.1988.tb10726.x","article-title":"Breast milk anti-Escherichia coli heat-labile toxin IgA antibodies protect against toxin-induced infantile diarrhea","volume":"77","author":"Cruz","year":"1988","journal-title":"Acta Paediatr Scand"},{"key":"10.1016\/j.vaccine.2023.01.033_b0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2011.05.021","article-title":"A systematic review of experimental infections with enterotoxigenic Escherichia coli (ETEC)","author":"Porter","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.01.033_b0100","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.4049\/jimmunol.1302743","article-title":"Intradermal delivery of Shigella IpaB and IpaD type III secretion proteins: kinetics of cell recruitment and antigen uptake, mucosal and systemic immunity, and protection across serotypes","volume":"192","author":"Heine","year":"2014","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2023.01.033_b0105","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1038\/mi.2011.6","article-title":"Transcutaneous immunization as preventative and therapeutic regimens to protect against experimental otitis media due to nontypeable Haemophilus influenzae","volume":"4","author":"Novotny","year":"2011","journal-title":"Mucosal Immunol"},{"key":"10.1016\/j.vaccine.2023.01.033_b0110","doi-asserted-by":"crossref","unstructured":"White JA, Blum JS, Hosken NA, Marshak JO, Duncan L, Zhu C, et al. Serum and mucosal antibody responses to inactivated polio vaccine after sublingual immunization using a thermoresponsive gel delivery system. Human Vaccine and Immunotherapeutics. 2014;In Press.","DOI":"10.4161\/hv.32253"},{"key":"10.1016\/j.vaccine.2023.01.033_b0115","article-title":"Fentanyl conjugate vaccine by injected or mucosal delivery with dmLT or LTA1 adjuvants implicates IgA in protection from drug challenge","volume":"6","author":"Addison","year":"2021","journal-title":"Nature Vaccines"},{"key":"10.1016\/j.vaccine.2023.01.033_b0120","doi-asserted-by":"crossref","DOI":"10.1128\/IAI.00460-19","article-title":"Intradermal or sublingual delivery and heat-labile enterotoxin (LT) proteins shape immunologic outcomes to CFA\/I fimbriae-derived subunit antigen vaccine against enterotoxigenic E. coli","author":"Maciel","year":"2019","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2023.01.033_b0125","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/j.vaccine.2018.12.011","article-title":"A Phase 1 dose escalating study of double mutant heat-labile toxin LTR192G\/L211A (dmLT) from Enterotoxigenic Escherichia coli (ETEC) by sublingual or oral immunization","volume":"37","author":"Bernstein","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.01.033_b0130","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1128\/CVI.00464-13","article-title":"Safety and immunogenicity of a single oral dose of recombinant double mutant heat-labile toxin derived from enterotoxigenic Escherichia coli","volume":"20","author":"El-Kamary","year":"2013","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2023.01.033_b0135","doi-asserted-by":"crossref","unstructured":"Tida Lee RLG, Milton Maciel, Steven Poole, Kayla J. Testa, Stefanie Trop, Christopher Duplessis, Alison Lane, Mark S. Riddle, Melinda Hamer, Ashley Alcala, Michael Prouty, Nicole Maier, Rahsan Erdem, A. Louis Bourgeois, and Chad K. Portera. Safety and immunogenicity of intramuscularly administered CS6 subunit vaccine with a modified heat-labile enterotoxin from enterotoxigenic Escherichia coli. Vaccine. 2021;39:5548-56.","DOI":"10.1016\/j.vaccine.2021.08.032"},{"key":"10.1016\/j.vaccine.2023.01.033_b0140","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1016\/j.vaccine.2022.03.056","volume":"40","author":"Crothers","year":"2022","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.01.033_b0145","doi-asserted-by":"crossref","unstructured":"Ann-Mari Svennerholm FQ, Anna Lundgren, Joanna Kaim, Taufiqur Rahman Bhuiyan, Marjahan Akhtar, Nicole Maier, A. Louis Bourgeois, Richard I. Walker. Induction of mucosal and systemic immune responses against the common O78 antigen of an oral inactivated ETEC vaccine in Bangladeshi children and infants. Vaccine. 2022;40:380-9.","DOI":"10.1016\/j.vaccine.2021.10.056"},{"key":"10.1016\/j.vaccine.2023.01.033_b0150","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/S1473-3099(19)30571-7","article-title":"Safety and immunogenicity of the oral, inactivated, enterotoxigenic Escherichia coli vaccine ETVAX in Bangladeshi children and infants: a double-blind, randomised, placebo-controlled phase 1\/2 trial","volume":"20","author":"Qadri","year":"2020","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2023.01.033_b0155","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.vaccine.2020.12.034","article-title":"Evaluation of the immunogenicity and protective efficacy of a recombinant CS6-based ETEC vaccine in an Aotus nancymaae CS6 + ETEC challenge model","volume":"39","author":"Ramakrishnan","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.01.033_b0160","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.vaccine.2015.11.017","article-title":"Immunogenicity of a prototype enterotoxigenic Escherichia coli adhesin vaccine in mice and nonhuman primates","volume":"34","author":"Sincock","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.01.033_b0165","doi-asserted-by":"crossref","first-page":"2880","DOI":"10.1016\/j.vaccine.2016.02.076","article-title":"Status of vaccine research and development for enterotoxigenic Escherichia coli","volume":"34","author":"Bourgeois","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.01.033_b0170","doi-asserted-by":"crossref","first-page":"4555","DOI":"10.1128\/IAI.00858-15","article-title":"Maternal vaccination with a fimbrial tip adhesin and passive protection of neonatal mice against lethal human enterotoxigenic Escherichia coli challenge","volume":"83","author":"Luiz","year":"2015","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2023.01.033_b0175","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1016\/j.vaccine.2015.02.069","article-title":"The novel adjuvant dmLT promotes dose sparing, mucosal immunity and longevity of antibody responses to the inactivated polio vaccine in a murine model","volume":"33","author":"Norton","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.01.033_b0180","doi-asserted-by":"crossref","first-page":"3471","DOI":"10.1016\/j.vaccine.2015.05.071","article-title":"Evaluating the value proposition for improving vaccine thermostability to increase vaccine impact in low and middle-income countries","volume":"33","author":"Christopher","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.01.033_b0185","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.654872","article-title":"dmLT Adjuvant Enhances Cytokine Responses to T Cell Stimuli, Whole Cell Vaccine Antigens and Lipopolysaccharide in Both Adults and Infants","volume":"12","author":"Akhtar","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2023.01.033_b0190","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2017.03.101","article-title":"Development of a candidate stabilizing formulation for bulk storage of a double mutant heat labile toxin (dmLT) protein based adjuvant","author":"Toprani","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.01.033_b0195","doi-asserted-by":"crossref","unstructured":"Toprani VM, Hickey JM, Sahni N, Toth RTt, Robertson GA, Middaugh CR, et al. Structural Characterization and Physicochemical Stability Profile of a Double Mutant Heat Labile Toxin Protein Based Adjuvant. J Pharm Sci. 2017;106:3474-85.","DOI":"10.1016\/j.xphs.2017.07.019"},{"key":"10.1016\/j.vaccine.2023.01.033_b0200","doi-asserted-by":"crossref","first-page":"10793","DOI":"10.1073\/pnas.0812843106","article-title":"Structure of CFA\/I fimbriae from enterotoxigenic Escherichia coli","volume":"106","author":"Li","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.vaccine.2023.01.033_b0205","doi-asserted-by":"crossref","DOI":"10.1128\/IAI.00788-18","article-title":"Biochemical and Immunological Evaluation of Recombinant CS6-Derived Subunit Enterotoxigenic Escherichia coli Vaccine Candidates","volume":"87","author":"Poole","year":"2019","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2023.01.033_b0210","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jim.2017.09.003","article-title":"Preformulation studies with the Escherichia coli double mutant heat-labile toxin adjuvant for use in an oral vaccine","volume":"451","author":"White","year":"2017","journal-title":"J Immunol Methods"},{"key":"10.1016\/j.vaccine.2023.01.033_b0215","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.ab.2013.02.014","article-title":"Monitoring protein aggregation kinetics with simultaneous multiple sample light scattering","volume":"437","author":"Drenski","year":"2013","journal-title":"Anal Biochem"},{"key":"10.1016\/j.vaccine.2023.01.033_b0220","first-page":"147","article-title":"Standardized methods for detection of poliovirus antibodies","volume":"1387","author":"Weldon","year":"2016","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.vaccine.2023.01.033_b0225","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/0014-5793(94)80635-7","article-title":"Structure of partially-activated E. coli heat-labile enterotoxin (LT) at 2.6 A resolution","volume":"337","author":"Merritt","year":"1994","journal-title":"FEBS Lett"},{"key":"10.1016\/j.vaccine.2023.01.033_b0230","doi-asserted-by":"crossref","first-page":"9361","DOI":"10.1021\/acs.jpcb.8b07820","article-title":"On the Reproducibility of Early-Stage Thermally Induced and Contact-Stir-Induced Protein Aggregation","volume":"122","author":"Jarand","year":"2018","journal-title":"The Journal of Physical Chemistry B"},{"key":"10.1016\/j.vaccine.2023.01.033_b0235","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.ab.2013.02.014","article-title":"Monitoring protein aggregation kinetics with simultaneous multiple sample light scattering","volume":"437","author":"Michael","year":"2013","journal-title":"Anal Biochem"},{"key":"10.1016\/j.vaccine.2023.01.033_b0240","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1093\/infdis\/147.3.514","article-title":"Serologic differentiation between antitoxin responses to infection with Vibrio cholerae and enterotoxin-producing Escherichia coli","volume":"147","author":"Svennerholm","year":"1983","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2023.01.033_b0245","article-title":"Vaccine-driven lung TRM cells provide immunity against Klebsiella via fibroblast IL-17R signaling","author":"Iwanaga","year":"202161198","journal-title":"Sci Immunol"},{"key":"10.1016\/j.vaccine.2023.01.033_b0250","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41541-021-00329-0","article-title":"Fentanyl conjugate vaccine by injected or mucosal delivery with dmLT or LTA1 adjuvants implicates IgA in protection from drug challenge","volume":"6","author":"Stone","year":"2021","journal-title":"npj Vaccines"},{"key":"10.1016\/j.vaccine.2023.01.033_b0255","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/mi.2007.7","article-title":"Cholera toxin, E. coli heat-labile toxin, and non-toxic derivatives induce dendritic cell migration into the follicle-associated epithelium of Peyer's patches","volume":"1","author":"Anosova","year":"2008","journal-title":"Mucosal Immunol"},{"key":"10.1016\/j.vaccine.2023.01.033_b0260","article-title":"Adjuvant selection regulates gut migration and phenotypic diversity of antigen-specific CD4(+) T cells following parenteral immunization","author":"Frederick","year":"2017","journal-title":"Mucosal Immunol"},{"key":"10.1016\/j.vaccine.2023.01.033_b0265","doi-asserted-by":"crossref","first-page":"360","DOI":"10.3389\/fimmu.2020.00360","article-title":"IL-33 Is Essential for Adjuvant Effect of Hydroxypropyl-beta-Cyclodexrin on the Protective Intranasal Influenza Vaccination","volume":"11","author":"Kobari","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2023.01.033_b0270","article-title":"Considerations for using ETEC and Shigella disease burden estimates to guide vaccine development strategy","author":"Hosangadi","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.01.033_b0275","doi-asserted-by":"crossref","first-page":"4","DOI":"10.7205\/MILMED-D-17-00064","article-title":"Travelers' Diarrhea: An Update on the Incidence, Etiology, and Risk in Military Deployments and Similar Travel Populations","volume":"182","author":"Porter","year":"2017","journal-title":"Mil Med"},{"key":"10.1016\/j.vaccine.2023.01.033_b0280","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1001\/jama.2014.17006","article-title":"Traveler's diarrhea: a clinical review","volume":"313","author":"Steffen","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2023.01.033_b0285","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1038\/nrgastro.2012.239","article-title":"The impoverished gut\u2013a triple burden of diarrhoea, stunting and chronic disease","volume":"10","author":"Guerrant","year":"2013","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.vaccine.2023.01.033_b0290","doi-asserted-by":"crossref","first-page":"3829","DOI":"10.4049\/jimmunol.1401633","article-title":"Cholera toxin, and the related nontoxic adjuvants mmCT and dmLT, promote human Th17 responses via cyclic AMP-protein kinase A and inflammasome-dependent IL-1 signaling","volume":"194","author":"Larena","year":"2015","journal-title":"J Immunol"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X23000555?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X23000555?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:22:59Z","timestamp":1759404179000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X23000555"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":58,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["S0264410X23000555"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2023.01.033","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Route and antigen shape immunity to dmLT-adjuvanted vaccines to a greater extent than biochemical stress or formulation excipients","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2023.01.033","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}